New report highlights fast growing market for Live Biotherapeutics, Destiny Pharma’s NTCD-M3 is leading play in this sector
New report highlights fast growing market for Live Biotherapeutics, Destiny Pharma’s NTCD-M3 is leading play in this sector
Monday November 14, 2022
A new report highlights a fast growing market for Live Biotherapeutics, reaching $2.6bn by 2030. Destiny Pharma’s NTCD-M3 preventing C. difficile infections is leading play in this sector. View the full report.